The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that ...
Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral ...
When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...
Teleflex has announced a plan to split its business into two separate independent companies—and it’s setting up one of its ...
Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...
Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...
The wearable cardiac monitor and defibrillator developer Kestra Medical Technologies aims to raise about $154 million by ...
AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...
Quest Diagnostics will take over the kidney-focused lab testing portfolio of the dialysis giant Fresenius Medical ...
Idorsia, which is no stranger to needing to find cash quickly, also said it has raised 150 million Swiss francs ($167 million ...
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results